Notably, a 60-year-old male patient (MM1), with IgA kappa MM and high-risk features (amp1q21 and t(14;20)) progressed after not more than two cycles of Daratumumab-Pomalidomide-Dexamethasone with low expression levels of FADD and BID and was bridged with KTD-PACE to subsequent BCMA-targeted CART cell therapy, to which he was responding with a complete remission (CR, Fig. 4c). This evidence concerns the gene CD79A and Miyoshi myopathy.